Positive Predictive Value (PPV) of Pseudomonas Aeruginosa
A Prospective, Single-blind Evaluation of the Positive Predictive Value (PPV) of the MolecuLight i:X™ Imaging Device to Predict the Presence of Pseudomonas Aeruginosa in Chronic Wounds
Sponsor: MolecuLight Inc.
Listed as NCT03290690, this observational or N/A phase trial focuses on Chronic Leg Ulcer and Wound and remains ongoing. Sponsored by MolecuLight Inc., it has been updated 11 times since 2017, reflecting substantial change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
11 versions recorded-
Sep 2025 — Present [monthly]
Unknown
-
Sep 2024 — Sep 2025 [monthly]
Unknown
-
Jul 2024 — Sep 2024 [monthly]
Unknown
Status: Unknown Status → Unknown
-
Apr 2022 — Jul 2024 [monthly]
Unknown Status
Status: Recruiting → Unknown Status
-
Jan 2021 — Apr 2022 [monthly]
Recruiting
▶ Show 6 earlier versions
-
Apr 2020 — Jan 2021 [monthly]
Recruiting
Status: Unknown Status → Recruiting
-
Jan 2020 — Apr 2020 [monthly]
Unknown Status
Status: Enrolling By Invitation → Unknown Status
-
Oct 2018 — Jan 2020 [monthly]
Enrolling By Invitation
-
Jun 2018 — Oct 2018 [monthly]
Enrolling By Invitation
-
Apr 2018 — Jun 2018 [monthly]
Enrolling By Invitation
Phase: NA → None
-
Oct 2017 — Apr 2018 [monthly]
Enrolling By Invitation NA
First recorded
Aug 2017
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- MolecuLight Inc.
- Scarborough Rouge Hospital
For direct contact, visit the study record on ClinicalTrials.gov .